A detailed history of Jpmorgan Chase & CO transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1 shares of BLRX stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1
Previous 1,501 99.93%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$0.53 - $0.87 $795 - $1,305
-1,500 Reduced 99.93%
1 $0
Q2 2024

Aug 12, 2024

BUY
$0.56 - $0.86 $840 - $1,290
1,501 New
1,501 $0
Q4 2023

Feb 12, 2024

BUY
$1.31 - $1.86 $30,093 - $42,727
22,972 New
22,972 $36,000

Others Institutions Holding BLRX

About BioLineRx Ltd.


  • Ticker BLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,524,500
  • Market Cap $26.5M
  • Description
  • BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...
More about BLRX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.